SS-31 (Elamipretide) Peptide

SS-31 (D-Arg-Dmt-Lys-Phe-NH₂) achieves mitochondrial targeting through its alternating aromatic-cationic motif. The mechanism involves multiple levels:

• Mitochondrial accumulation: The cationic charges (+3 at pH 7.4) drive >1,000-fold concentration within mitochondria via the large negative membrane potential (ΔΨm ≈ -180 mV) across the inner membrane
• Cardiolipin binding: Once in the inner membrane, SS-31 binds cardiolipin through electrostatic (Arg, Lys) and hydrophobic (Dmt, Phe) interactions. Cardiolipin is unique to mitochondria and essential for electron transport chain function
• Electron transport optimization: SS-31 binding prevents cytochrome c from converting to a peroxidase (a pathological conformational change), maintaining it as an efficient electron carrier between Complex III and IV
• ROS reduction: By optimizing electron flow, SS-31 reduces electron leakage at Complex I and III — the primary sites of mitochondrial superoxide generation. ROS production decreases without compromising ATP synthesis

This mechanism is fundamentally different from antioxidants (which scavenge ROS after production) — SS-31 prevents excessive ROS generation at the source while improving energy production.

Reconstitution solvent selection: SS-31 (elamipretide) is highly water-soluble owing to its net positive charge (+3 at physiological pH from the D-Arg guanidinium, Lys ε-amine, and free N-terminus). Bacteriostatic water for injection (0.9% benzyl alcohol) is the standard reconstitution vehicle for laboratory research applications and maintains a mildly acidic pH that favors peptide stability. Sterile water for injection or 0.9% sodium chloride are acceptable alternatives where a preservative-free vehicle is required.

Reconstitution procedure: Allow the lyophilized vial to equilibrate to room temperature (approximately 20 minutes) before opening to prevent moisture condensation. Wipe the rubber stopper with 70% isopropanol. Using a sterile syringe, slowly inject the calculated volume of reconstitution solvent down the inner glass wall of the vial rather than directly onto the powder cake; this minimizes mechanical disruption and foaming. Gently swirl—do not shake or vortex vigorously—until the powder is fully dissolved (typically within 30–60 seconds given the small tetrapeptide size of 639.8 Da for the acetate salt or 595.7 Da for the free base).

Concentration calculations:

• 5 mg vial + 1.0 mL diluent = 5.0 mg/mL stock
• 5 mg vial + 2.0 mL diluent = 2.5 mg/mL stock
• 10 mg vial + 2.0 mL diluent = 5.0 mg/mL stock

For low-concentration working solutions (below 0.1 mg/mL), prepare immediately before use to minimize surface adsorption losses.

Structural considerations affecting handling: The peptide sequence is H-D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is the non-proteinogenic 2,6-dimethyltyrosine. The D-arginine residue confers resistance to most aminopeptidases, contributing to the relatively long plasma half-life observed in preclinical pharmacokinetic studies. The C-terminal amide further protects against carboxypeptidase action. These features mean SS-31 is more robust than typical L-amino-acid tetrapeptides during routine handling.

Light protection: The 2,6-dimethylated tyrosine ring is the principal photosensitive moiety. Perform reconstitution under reduced ambient light, ideally using amber glass vials or vials wrapped in aluminum foil. Avoid direct exposure to fluorescent or UV laboratory lighting for periods exceeding a few minutes during manipulation. Photo-oxidation generates inactive ortho-quinone and dityrosine-crosslinked products that diminish biological activity.

Surface adsorption: Cationic peptides can adsorb to glass and polypropylene surfaces. For dilute working solutions (<0.01 mg/mL), use low-binding polypropylene tubes (e.g., Eppendorf LoBind) and consider pre-rinsing pipette tips with the diluent. The addition of 0.01–0.1% bovine serum albumin or 0.01% polysorbate-80 can reduce adsorption losses when preparing very dilute solutions for in vitro assays, though this should be omitted when carrier protein interferes with downstream readouts.

Aliquoting: For experiments requiring multiple uses of a single reconstituted vial, prepare single-use aliquots in low-binding tubes immediately after reconstitution and freeze at -20°C. Thaw individual aliquots only as needed. Avoid more than one freeze-thaw cycle per aliquot.

Sterility and contamination: Use aseptic technique throughout. Bacteriostatic water provides limited antimicrobial activity but is not a substitute for sterile handling.

pH and buffer compatibility: SS-31 is compatible with most physiologically relevant buffers (PBS, HBSS, HEPES-buffered media) at pH 4.0–7.4. Avoid alkaline conditions and avoid contact with copper or iron salts that catalyze oxidation of the Dmt residue.

For laboratory research use only. Not for human or veterinary administration.

Lyophilized powder: Store at -20°C in a sealed, desiccated container for up to 24 months from the date of synthesis. For long-term archival storage exceeding two years, -80°C is preferred to minimize residual moisture-driven hydrolysis. The lyophilized form is hygroscopic; allow vials to equilibrate to room temperature for 20–30 minutes before opening to prevent atmospheric moisture condensation onto the powder, which can initiate localized hydrolysis of peptide bonds.

Reconstituted solution: After dissolution in bacteriostatic water or sterile saline, store at 2–8°C and use within 14 days. For extended storage of reconstituted material, single-use aliquots can be frozen at -20°C for up to 60 days, although repeated freeze-thaw cycles should be strictly avoided as they promote peptide aggregation and loss of biological activity. Each freeze-thaw cycle can reduce potency by an estimated 5–10% for small tetrapeptides.

Photosensitivity considerations: SS-31 contains a 2,6-dimethyltyrosine (Dmt) residue at position 1, which is the principal chromophore and is sensitive to UV and short-wavelength visible light. Photo-oxidation of the phenolic ring can generate inactive degradation products, including dityrosine crosslinks and ortho-quinone derivatives. All storage and handling should be performed under amber glass, in foil-wrapped vials, or under low-intensity yellow lighting. Laboratory benches with fluorescent overhead lighting are acceptable for brief manipulations but prolonged exposure should be avoided.

Temperature excursions: Short transit exposure (up to 7 days) at ambient temperature (15–25°C) does not appreciably degrade the lyophilized powder, owing to the inherent thermal stability of the four-residue backbone (D-Arg-Dmt-Lys-Phe-NH₂). Brief excursions to 30–35°C during shipping have been reported as acceptable for related Szeto-Schiller peptides without significant loss of mitochondrial-targeting activity, but cumulative thermal load should be minimized.

Container and material compatibility: Use borosilicate glass or low-binding polypropylene vials. Standard polypropylene microcentrifuge tubes can adsorb 1–3% of dissolved peptide via hydrophobic surface interactions; low-protein-binding (Eppendorf LoBind or equivalent) tubes are recommended for stock solutions below 1 mg/mL. Avoid contact with metal cations such as Cu²⁺ and Fe³⁺, which can catalyze oxidation of the Dmt residue.

pH and buffer stability: SS-31 is most stable at slightly acidic pH (4.0–6.0). At alkaline pH (>8.0), the free amino terminus and lysine ε-amine become deprotonated and more susceptible to oxidative and carbamylation reactions. Bacteriostatic water (0.9% benzyl alcohol) typically maintains pH near 5.0–5.5, which is favorable for the cationic peptide.

Visual inspection: Lyophilized SS-31 should appear as a white to off-white amorphous powder or fluffy cake. Reconstituted solutions should be clear and colorless. Any yellow tint, visible particulates, or cloudiness indicates oxidation or aggregation and the material should be discarded. Periodic LC-MS or HPLC purity verification is recommended for stocks held longer than 6 months.

Research use only: This material is intended exclusively for in vitro and preclinical laboratory investigation. It is not for human or veterinary use.